Drug Pipeline

August 13, 2021

Accelerated approval and use of surrogate markers are among the friction points. But some see the OK as spawning a new generation of drug development for treating Alzheimer’s disease.

July 12, 2021

Not in recent memory has an FDA approval stirred up so much controversy as the agency’s OK of Aduhelm, Biogen’s Alzheimer’s treatment.

June 16, 2021

In this part five series, participants give their opinions on which drugs newer to the market in the last 12 months hold the most promise to reducing morbidity and mortality. Participants also shared which drug in the pipeline holds the most promise. MHE's annual pharmacy survey had over 225 respondents. We will be posting the results over the next few days.

June 08, 2021

The jury is still out. Several companies have high hopes for candidates under development.

May 12, 2021

Longer half-lives mean less frequent administration and improved quality of life.

May 06, 2021

The Institute for Clinical and Economic Review's price range is far below the $50,000 per year envisioned by some market analysts.

April 16, 2021

In this third part of a three-part series, Steven D. Pearson, M.D., M.Sc., founder and president of ICER talks the drug Inclisiran and its relation to PCSK9 inhibitors.

April 15, 2021

The triptans, long the workhorses of migraine treatment, have been joined by monoclonal antibodies and small-molecule drugs that block calcitonin gene-related peptide. What’s lacking is a precision approach to treatment based on biomarkers.

March 08, 2021

Will emerging variants make the leading vaccines less protective?

February 01, 2021

Opinion piece by MHE's Editorial Advisory Board Member and CEO of The Pharmacy Group, Perry Cohen. Perry discusses the response differences and vague similarities between the countries and addresses the continuous question, "What is the new normal?"